OtherGastrointestinal, Hepatic, Pulmonary, and Renal
The GPR40 full agonist SCO-267 improves liver parameters in a mouse model of nonalcoholic fatty liver disease without affecting glucose or body weight
Mitsugi Ookawara, Keisuke Matsuda, Masanori Watanabe and Yusuke Moritoh
Journal of Pharmacology and Experimental Therapeutics July 27, 2020, JPET-AR-2020-000046; DOI: https://doi.org/10.1124/jpet.120.000046
Mitsugi Ookawara
1SCOHIA PHARMA, Inc., Japan
Keisuke Matsuda
1SCOHIA PHARMA, Inc., Japan
Masanori Watanabe
1SCOHIA PHARMA, Inc., Japan
Yusuke Moritoh
1SCOHIA PHARMA, Inc., Japan
Jump to comment:
No eLetters have been published for this article.
In this issue
OtherGastrointestinal, Hepatic, Pulmonary, and Renal
GPR40 full agonist for nonalcoholic fatty liver disease
Mitsugi Ookawara, Keisuke Matsuda, Masanori Watanabe and Yusuke Moritoh
Journal of Pharmacology and Experimental Therapeutics July 27, 2020, JPET-AR-2020-000046; DOI: https://doi.org/10.1124/jpet.120.000046
OtherGastrointestinal, Hepatic, Pulmonary, and Renal
GPR40 full agonist for nonalcoholic fatty liver disease
Mitsugi Ookawara, Keisuke Matsuda, Masanori Watanabe and Yusuke Moritoh
Journal of Pharmacology and Experimental Therapeutics July 27, 2020, JPET-AR-2020-000046; DOI: https://doi.org/10.1124/jpet.120.000046
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement